Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
On Tuesday, H.C. Wainwright stood by its Buy rating and $30.00 price target for BioCryst Pharma (NASDAQ:BCRX), despite the stock’s recent 11% decline over the past week. According to InvestingPro data, analyst targets range from $8 to $30, with a consensus recommendation leaning towards Buy. The firm’s confidence in the company is bolstered by its optimistic view of BCX17725, a fusion protein KLK5 inhibitor that is currently being developed to treat Netherton syndrome, a rare and severe genetic skin disorder.
BioCryst’s BCX17725 targets a significant unmet need within the rare disease market, as Netherton syndrome lacks an approved disease-modifying therapy. The company has shown strong commercial execution, with revenue growing 36% over the last twelve months to $450.7 million. The condition is characterized by a mutation in the SPINK5 gene, which affects the production of LEKTI, a crucial serine protease inhibitor. This mutation leads to unregulated activity of certain proteases like KLK5, which are important in skin shedding and inflammation, both of which are central to Netherton syndrome.
Analysts at H.C. Wainwright believe that targeting KLK5 could offer a disease-modifying approach, rather than merely managing symptoms. The significance of BCX17725 lies in its potential to inhibit KLK5, which is upstream of other proteases involved in the disease’s pathology. The therapy’s focus on the underlying cause of Netherton syndrome could represent a major breakthrough for patients.
Currently, there are approximately 1,600 patients diagnosed with Netherton syndrome in the United States. H.C. Wainwright suggests that this number could grow to 5,000 with the availability of an approved therapy, indicating a substantial market opportunity for BioCryst.
The firm’s reiterated Buy rating and price target reflect its belief in the potential of BCX17725 to become a significant asset for BioCryst, as well as the company’s prospects for growth within the rare disease sector. InvestingPro analysis shows the company maintains a "GREAT" overall financial health score, though it’s currently not profitable. For deeper insights into BioCryst’s financial health and growth potential, including exclusive ProTips and comprehensive analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, BioCryst Pharmaceuticals reported a fourth-quarter 2024 revenue of $131.53 million, surpassing the consensus estimate of $127.17 million, marking a 40.8% year-over-year increase. However, the company missed earnings per share (EPS) expectations with a reported loss of $0.13, compared to the anticipated loss of $0.07. Despite this, BioCryst has raised its 2025 revenue guidance for Orladeyo, its key treatment, to between $535 million and $550 million, up from a previous range of $515 million to $535 million. Analysts from Piper Sandler and Citizens JMP have maintained their positive ratings on BioCryst, with Piper Sandler setting a price target of $23.00 and Citizens JMP holding a target of $18.00. The Inflation Reduction Act has been cited as a significant factor in improving the affordability of Orladeyo for Medicare patients, potentially boosting patient retention. The company is also investing in its pipeline, with advancements in treatments for Netherton syndrome and diabetic macular edema. BioCryst’s strategic outlook includes achieving $1 billion in peak worldwide sales for Orladeyo, with a substantial portion expected from the U.S. market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.